Mobidiag, a Finnish molecular diagnostics company, announced that it will offer the Amplidiag product line in South Africa through a distribution agreement with PerkinElmer’s Wallac Oy subsidiary.
The Amplidiag product line includes in vitro diagnostic tests and compatible systems for the detection of gastrointestinal infections.
“Thanks to a large distribution network, our Amplidiag product line is now accessible in most European countries. Our ambition is now to expand our coverage worldwide and towards new markets, starting with Africa.
“In order to develop ourselves in this specific market, we were looking for a distributor with acknowledged expertise and worldwide leadership in the field of diagnostics. We are then very happy that PerkinElmer agreed to accompany us in this great endeavor,” said Tuomas Tenkanen, CEO at Mobidiag.
“PerkinElmer continues to expand our infectious disease offerings in regions such as Africa to help meet the health needs of these populations,” said Hanna Halme, PerkinElmer’s Vice-President for EMEA.
The agreement is effective immediately and covers all Amplidiag IVD tests (Amplidiag H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag C. difficile+027, Amplidiag® Bacterial GE and upcoming Amplidiag Viral GE) as well as the Amplidiag® Easy system.
Amplidiag assays are innovative multiplex tests for the detection of gastrointestinal infections. They allow screening of panels of the most relevant gastrointestinal pathogens.
Based on well-established real-time PCR technology, they ensure optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings. In addition, Mobidiag allows process automation from sample extraction to PCR set-up with the Amplidiag® Easy system.